Denali Therapeutics Inc. (DNLI)
Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI
Cantor Fitzgerald L. P. acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 45,000 shares of the company's stock, valued at approximately $653,000. A number of other hedge funds and other institutional investors
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing course.
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
3 Biotech Stocks That Could Double In 2026
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
3 Biotech Stocks With Major 2026 Catalysts
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Denali Enters Into a $275M Funding Deal With Royalty Pharma
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali: Regulatory Delay Is A Strategic Opportunity
Denali Therapeutics (DNLI) is transitioning from a clinical-stage to a commercial-stage biotech, leveraging its innovative blood-brain barrier Transport Vehicle platform. DNLI's financials reflect increased investment in manufacturing and commercialization, with sufficient cash runway (~1.5 years) to support upcoming product launches. Tividenofusp Alfa (DNL310) for MPS II is the lead candidate, with FDA review delayed to April 2026 but no major clinical concerns cited by regulators.
